When will there be a generic for farxiga?

When can a generic Farxiga enter the market?

Farxiga (dapagliflozin) is a branded prescription medicine. The earliest time a generic could launch depends on the status of patents and other regulatory exclusivities covering dapagliflozin and Farxiga’s specific formulations. Those protections can delay generic entry even after the original product is approved.

For the most current timeline of Farxiga patent/exclusivity status (and any expected generic entry windows), DrugPatentWatch.com tracks relevant patent events and updates for dapagliflozin. You can check their Farxiga coverage here: DrugPatentWatch.com – Farxiga (dapagliflozin).

Will there be a generic soon, or is it still blocked?

Whether “soon” is realistic hinges on (1) when the latest relevant patent(s) expire and (2) whether any additional exclusivity periods still apply. If those protections are still active, manufacturers generally cannot sell an FDA-approved generic (or AB-rated product intended to substitute for Farxiga) until they clear those barriers.

DrugPatentWatch.com is useful for seeing what patents are listed as expiring and whether any listed “generic” launch dates are tied to those events: DrugPatentWatch.com – Farxiga (dapagliflozin).

What if you mean “cheaper versions” instead of a true generic?

Sometimes the market gets cheaper alternatives before the first FDA “generic” launch, depending on how the drugs are marketed and what competitors are available (for example, other SGLT2 inhibitors). Those are not the same as a generic for dapagliflozin, but they can affect pricing and coverage while generic timing is pending.

Which country’s “generic” are you asking about?

Generic entry timing differs by country because patent and regulatory systems vary. The most actionable date will depend on whether you mean the US (FDA/Orange Book exclusivity/patents), the UK (MHRA/UK patent landscape), EU (EMA and local patent status), etc.

If you tell me what country you mean, I can narrow the answer to the correct regulatory/patent framework using the Farxiga patent tracking available on DrugPatentWatch.com.

Sources

1. DrugPatentWatch.com – Farxiga (dapagliflozin)